

Claims:

1. ZnT-1 for use as a cellular L-type calcium channel (LTCC) blocker, which blocker has the properties of:
 - (a) a modulator of LTCC function; and
 - (b) a modulator of intracellular calcium concentration.
2. ZnT-1 of claim 1, for use as an LTCC blocker in the treatment and/or prevention of cardiovascular diseases and related indications.
3. ZnT-1 of any one of claims 1 and 2, for use in the treatment and/or prevention of hypertension and stroke.
4. ZnT-1 of any one of claims 1 to 3, wherein said ZnT-1 is active in any one of vascular, brain or heart cells.
5. A composition for blocking L-type calcium channels, comprising as active agent ZnT-1, and optionally comprising pharmaceutically acceptable adjuvant, carrier, diluent or excipient.
6. The composition of claim 5, for the treatment and/or prevention of cardiovascular diseases and related indications.
7. The composition of claim 6, for the treatment and/or prevention of hypertension and stroke.
8. A method of treating cardiovascular disorders in a patient in need of such treatment, comprising administering to said patient ZnT-1 or the composition of any one of claims 5 to 7.

9. Use of ZnT-1 in the preparation of a pharmaceutical composition for the treatment and/or prevention of cardiovascular diseases and related indications, preferably said cardiovascular diseases are hypertension and stroke.